News Updates

More Articles Back to Article

BioNTech, OncoC4 sign licensing deal for CTLA-4 antibody

BioNTech said it has signed an exclusive global licensing and collaboration deal with OncoC4 for the development and commercialization of its anti-CTLA-4 antibody candidate ONC-392 for solid tumors. As part of the agreement, a $200 million upfront payment will be made to OncoC4, which will also be eligible for milestone payments related to commercial, development and regulatory achievements as well as double-digit tiered royalty payments. BioSpace (San Francisco) (3/21)


文章仅仅是 DIA 会员的专享福利之一。了解详情并立即加入,不再错过任何文章!